Supreme Court Should Pass On Zarxio, Wait For Another Biosimilar Suit, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz's petition challenging biosimilar launch notification requirements isn't urgent, Amgen argues, but if court takes up case, Amgen also wants it to rule on whether patent dance is optional.